Feasibility and Ethical Issues: Experiences and Concerns of Healthcare Workers Regarding a New RSV Prophylaxis Programme in Nunavik, Quebec

Overview

Journal Int J Circumpolar Health

Date 2020 Mar 20

PMID 32191589

Citations 5

Authors

Armelle Lorcy

Rodica Gilca

Eve Dube

Marie Rochette

Gaston De Serres

Affiliations

Soon will be listed here.

Abstract

: The respiratory syncytial virus (RSV) is a major cause of hospitalisation in young Inuit children. Prophylaxis with palivizumab is routinely recommended for premature infants and those with severe pulmonary or cardiac diseases. In the fall 2016, the Quebec Ministry of Health expanded the criteria to include healthy full-term (HFT) newborns from Nunavik based on their high RSV hospitalisation rates.: The aim of this study was to describe the impact of this programme on Nunavik health services during the first RSV season after its implementation (2016-2017) by studying challenges, concerns and needs of healthcare workers (HCWs).: An ethnographic approach was used. Semi-structured interviews focusing on HCWs experiences, and opinions to improve the new programme were conducted with 20 HCWs involved in its implementation.: Main reported challenges and concerns were: additional work(over)load, lack of information and evidence about the need and efficacy of palivizumab in HFT newborns, communication issues between stakeholders, and ethical issues regarding the Inuit population.: The study revealed significant feasibility and acceptability issues. The programme was highly resource consuming. To address HCWs' concerns, evidence-based data regarding palivizumab effectiveness in HFT infants, as well as consultation and involvement of Inuit population are warranted.

Citing Articles

Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review.

Gavaruzzi T, Ceccarelli A, Nanni C, Vignali C, Colonnello V, Caserotti M Vaccines (Basel). 2025; 13(2).

PMID: 40006706 PMC: 11861692. DOI: 10.3390/vaccines13020159.

Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada.

Bugden S, Mital S, Nguyen H BMC Med. 2025; 23(1):102.

PMID: 39984979 PMC: 11846277. DOI: 10.1186/s12916-025-03928-z.

Infectious diseases in Indigenous populations in North America: learning from the past to create a more equitable future.

Lee N, King A, Vigil D, Mullaney D, Sanderson P, Ametepee T Lancet Infect Dis. 2023; 23(10):e431-e444.

PMID: 37148904 PMC: 10156139. DOI: 10.1016/S1473-3099(23)00190-1.

Urgent air transfers for acute respiratory infections among children from Northern Canada, 2005-2014.

Prendergast C, Robinson J, Caya C, Perez Trejo M, Guan I, Hebert-Murakami V PLoS One. 2022; 17(7):e0272154.

PMID: 35901042 PMC: 9333212. DOI: 10.1371/journal.pone.0272154.

RSV disease in infants and young children: Can we see a brighter future?.

Baraldi E, Lisi G, Costantino C, Heinrichs J, Manzoni P, Ricco M Hum Vaccin Immunother. 2022; 18(4):2079322.

PMID: 35724340 PMC: 9721445. DOI: 10.1080/21645515.2022.2079322.

References

Smylie J, Kirst M, McShane K, Firestone M, Wolfe S, OCampo P . Understanding the role of Indigenous community participation in Indigenous prenatal and infant-toddler health promotion programs in Canada: A realist review. Soc Sci Med. 2016; 150:128-43. DOI: 10.1016/j.socscimed.2015.12.019. View

Singleton R, Dooley L, Bruden D, Raelson S, Butler J . Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J. 2003; 22(6):540-5. DOI: 10.1097/01.inf.0000069768.34383.18. View

Banerji A, Panzov V, Young M, Lee B, Mamdani M, Giles B . The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut. Can Respir J. 2013; 21(3):185-9. PMC: 4128465. DOI: 10.1155/2014/941367. View

Singleton R, Bruden D, Brooks L, DeLeon J, Vercelline A, Butler J . Closer to home: local care improves compliance with RSV prophylaxis in high-risk infants. Int J Circumpolar Health. 2006; 65(1):4-7. DOI: 10.3402/ijch.v65i1.17886. View

Kua K, Lee S . Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis. Pharmacotherapy. 2017; 37(6):755-769. DOI: 10.1002/phar.1936. View

Burns P, Rohrich R, Chung K . The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011; 128(1):305-310. PMC: 3124652. DOI: 10.1097/PRS.0b013e318219c171. View

Jenkins A, Gyorkos T, Culman K, Ward B, Pekeles G, Mills E . An overview of factors influencing the health of Canadian Inuit infants. Int J Circumpolar Health. 2003; 62(1):17-39. DOI: 10.3402/ijch.v62i1.17526. View

Paquin V, Sandy G, Perrault-Sullivan G, Fortin G, Cauchon M, Fletcher C . Twenty "must-read" research articles for primary care providers in Nunavik: scoping study and development of an information tool. Int J Circumpolar Health. 2019; 78(1):1578638. PMC: 6407590. DOI: 10.1080/22423982.2019.1578638. View

Banerji A, Panzov V, Young M, Robinson J, Lee B, Moraes T . Hospital admissions for lower respiratory tract infections among infants in the Canadian Arctic: a cohort study. CMAJ Open. 2016; 4(4):E615-E622. PMC: 5173479. DOI: 10.9778/cmajo.20150051. View

10.

Simoes E, Bont L, Manzoni P, Fauroux B, Paes B, Figueras-Aloy J . Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018; 7(1):87-120. PMC: 5840107. DOI: 10.1007/s40121-018-0188-z. View

11.

Healey G, Meadows L . Inuit women's health in Nunavut, Canada: a review of the literature. Int J Circumpolar Health. 2007; 66(3):199-214. DOI: 10.3402/ijch.v66i3.18256. View

12.

Zhou H, Thompson W, Viboud C, Ringholz C, Cheng P, Steiner C . Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012; 54(10):1427-36. PMC: 3334364. DOI: 10.1093/cid/cis211. View

13.

. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics. 1998; 102(3):531-7. View

14.

Shi T, McAllister D, OBrien K, Simoes E, Madhi S, Gessner B . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017; 390(10098):946-958. PMC: 5592248. DOI: 10.1016/S0140-6736(17)30938-8. View

15.

Gautier L, Pirkle C, Furgal C, Lucas M . Assessment of the implementation fidelity of the Arctic Char Distribution Project in Nunavik, Quebec. BMJ Glob Health. 2017; 1(3):e000093. PMC: 5321351. DOI: 10.1136/bmjgh-2016-000093. View

16.

Feltes T, Cabalka A, Meissner H, Piazza F, Carlin D, Top Jr F . Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003; 143(4):532-40. DOI: 10.1067/s0022-3476(03)00454-2. View

17.

Andabaka T, Nickerson J, Rojas-Reyes M, Rueda J, Vrca V, Barsic B . Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013; (4):CD006602. DOI: 10.1002/14651858.CD006602.pub4. View

18.

Bruden D, Singleton R, Hawk C, Bulkow L, Bentley S, Anderson L . Eighteen Years of Respiratory Syncytial Virus Surveillance: Changes in Seasonality and Hospitalization Rates in Southwestern Alaska Native Children. Pediatr Infect Dis J. 2015; 34(9):945-50. PMC: 6931377. DOI: 10.1097/INF.0000000000000772. View

19.

Hordyk S, Macdonald M, Brassard P . Inuit interpreters engaged in end-of-life care in Nunavik, Northern Quebec. Int J Circumpolar Health. 2017; 76(1):1291868. PMC: 5345586. DOI: 10.1080/22423982.2017.1291868. View

20.

Cerigo H, Macdonald M, Franco E, Brassard P . Inuit women's attitudes and experiences towards cervical cancer and prevention strategies in Nunavik, Quebec. Int J Circumpolar Health. 2012; 71:17996. PMC: 3417708. DOI: 10.3402/ijch.v71i0.17996. View